← Back to Search

Screening Program for Multiple Myeloma

N/A

Recruiting

Led By Jason Valent, MD

Research Sponsored by Case Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

50 years of age or older

Be older than 18 years old

Must not have

Under the age of 50 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial seeks to develop a program to better understand and detect multiple myeloma early, including analyzing community understanding and participation in screening, and providing patient navigation for those with abnormal results. #MM #Screening

Who is the study for?

This trial is for Black and/or African-American individuals who are 50 years or older. It aims to promote early detection of multiple myeloma by screening participants and providing guidance if abnormal results are found.

What is being tested?

The study tests a community outreach program that includes MM screening using M-Protein analysis, followed by patient navigation for those with abnormal results. It also assesses participant knowledge about MM through questionnaires.

What are the potential side effects?

Since this trial involves screening and questionnaires rather than medical treatments, there are no direct side effects associated with the interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 50 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am under 50 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

To conduct and evaluate a study that incorporates patient navigation programs to recruit and screen participants for Multiple Myeloma and its disease precursors, MGUS or smoldering MM

To study participant knowledge of Multiple Myeloma

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Multiple Myeloma Screening ExperienceExperimental Treatment2 Interventions

Participants will partake in a multiple myeloma screening program. The screening involves a blood sample and the completion of a questionnaire to gauge participants' multiple myeloma knowledge.

0 / 2Eligibility criteria met